PillInsulin Glargine
Brands: Basaglar Kwikpen · Basaglar Tempo Pen · Lantus Solostar · Lantus +2 · Insulin Glargine
3 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 8 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | unknown | 10 | SUPPLYING |
| A-S Medication Solutions | unknown | 6 | SUPPLYING |
| Eli Lilly and Company | unknown | 3 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Oct 24, 2025RESOLVEDShortage resolved: Insulin Glargine Injection (Eli Lilly and Co.)
Insulin Glargine Injection — reported in shortage by Eli Lilly and Co.. Therapeutic category: Endocrinology/Metabolism.
- Oct 24, 2025SHORTAGEDrug shortage: Insulin Glargine Injection (Eli Lilly and Co.)
Insulin Glargine Injection — reported in shortage by Eli Lilly and Co.. Therapeutic category: Endocrinology/Metabolism.